Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average ...

The leading Cystic Fibrosis Companies such as Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant ...

Nearly $30 million in tax incentive awards are expected to add 1,519 new life sciences jobs in Massachusetts, with about 52% ...

Aries Wealth Management has tiptoed into biotech by acquiring 605 shares of Vertex Pharmaceuticals, valued around $293,000. Other hedge funds also took notice, adjusting their positions during the ...

Sage Therapeutics Inc. has found itself a buyer that bested the unsolicited acquisition offer a few months ago from fellow ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

CCM Investment Advisers gave Vertex Pharmaceuticals a vitamin shot by upping its stake 24.1% in Q1. They purchased an ...

Buy-and-hold investing is a time-tested strategy that rewards patience and discipline. By owning high-quality stocks for at ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $455.45, denoting a -1% move from the preceding trading day.

The stock's fall snapped a three-day winning streak.

The biotech, known as the developer of the first CRISPR drug, will consolidate sites in the state as it stops developing a diabetes cell therapy.